Spasticity
A motor disorder characterized by velocity-dependent increase in muscle tone, resulting from upper motor neuron lesions. A primary indication for nabiximols (Sativex) in multiple sclerosis.
In Depth
MS-related spasticity affects 60–90% of people with MS and significantly impairs quality of life. Nabiximols (Sativex) is approved in over 30 countries for MS spasticity based on multiple RCTs showing significant reductions in patient-reported spasticity scores. The mechanism involves CB1 receptor-mediated reduction of glutamate and GABA release in spinal cord circuits. THC is the primary active component for spasticity, with CBD potentially moderating adverse effects.
Related Terms
Further Reading
More in Clinical
Dravet Syndrome
A severe, treatment-resistant form of childhood epilepsy characterized by prolonged seizures, often triggered by fever, beginning in the first year of life.
Lennox-Gastaut Syndrome (LGS)
A severe form of childhood-onset epilepsy characterized by multiple seizure types, slow spike-wave EEG pattern, and cognitive impairment.
Epidiolex
The FDA-approved pharmaceutical formulation of purified cannabidiol (CBD), manufactured by GW Pharmaceuticals (now Jazz Pharmaceuticals). Approved in 2018 for Dravet syndrome and Lennox-Gastaut syndrome.
Dronabinol (Marinol)
A synthetic form of THC (Δ9-tetrahydrocannabinol) approved by the FDA for chemotherapy-induced nausea/vomiting and AIDS-related anorexia.
Nabilone (Cesamet)
A synthetic cannabinoid analogue of THC approved for chemotherapy-induced nausea and vomiting. More potent than dronabinol.